These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 15977303

  • 1. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954.
    de Poorter JJ, Tolboom TC, Rabelink MJ, Pieterman E, Hoeben RC, Nelissen RG, Huizinga TW.
    J Gene Med; 2005 Nov; 7(11):1421-8. PubMed ID: 15977303
    [Abstract] [Full Text] [Related]

  • 2. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
    Grove JI, Lovering AL, Guise C, Race PR, Wrighton CJ, White SA, Hyde EI, Searle PF.
    Cancer Res; 2003 Sep 01; 63(17):5532-7. PubMed ID: 14500391
    [Abstract] [Full Text] [Related]

  • 3. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
    Mitchell DJ, Minchin RF.
    Cancer Gene Ther; 2008 Nov 01; 15(11):758-64. PubMed ID: 18600257
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
    Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, Anlezark GM, Michael NP, Melton RG, Ford MJ, Young LS, Kerr DJ, Searle PF.
    Cancer Gene Ther; 1997 Nov 01; 4(4):229-38. PubMed ID: 9253508
    [Abstract] [Full Text] [Related]

  • 6. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
    Drabek D, Guy J, Craig R, Grosveld F.
    Gene Ther; 1997 Feb 01; 4(2):93-100. PubMed ID: 9081711
    [Abstract] [Full Text] [Related]

  • 7. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
    McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, Searle PF.
    Gene Ther; 1998 Aug 01; 5(8):1061-9. PubMed ID: 10326029
    [Abstract] [Full Text] [Related]

  • 8. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
    Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, Patterson AV, Ackerley DF.
    Biochem Pharmacol; 2010 Mar 01; 79(5):678-87. PubMed ID: 19852945
    [Abstract] [Full Text] [Related]

  • 9. Virus-directed enzyme prodrug therapy using CB1954.
    Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ.
    Anticancer Drug Des; 1999 Dec 01; 14(6):461-72. PubMed ID: 10834268
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP, Searle PF, Mautner V, James ND.
    Cancer Res; 2000 Jan 15; 60(2):334-41. PubMed ID: 10667585
    [Abstract] [Full Text] [Related]

  • 14. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
    Blackwood L, O'Shaughnessy PJ, Reid SW, Argyle DJ.
    Vet J; 2001 May 15; 161(3):269-79. PubMed ID: 11352484
    [Abstract] [Full Text] [Related]

  • 15. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.
    Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Evans TR, Ganly I, Knox RJ, Plumb JA, Keith WN.
    Oncogene; 2003 Jan 23; 22(3):370-80. PubMed ID: 12545158
    [Abstract] [Full Text] [Related]

  • 16. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
    Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI.
    Clin Exp Pharmacol Physiol; 2004 Nov 23; 31(11):811-6. PubMed ID: 15566399
    [Abstract] [Full Text] [Related]

  • 17. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
    Westphal EM, Ge J, Catchpole JR, Ford M, Kenney SC.
    Cancer Gene Ther; 2000 Jan 23; 7(1):97-106. PubMed ID: 10678362
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP, Anderson RF, Ferry DM, Wilson WR, Denny WA.
    J Med Chem; 2003 Dec 04; 46(25):5533-45. PubMed ID: 14640560
    [Abstract] [Full Text] [Related]

  • 19. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.
    Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ.
    Hum Gene Ther; 1997 Apr 10; 8(6):709-17. PubMed ID: 9113510
    [Abstract] [Full Text] [Related]

  • 20. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
    Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill S, Harris PA, Searle PF, Young LS, James ND, Kerr DJ.
    J Clin Oncol; 2004 May 01; 22(9):1546-52. PubMed ID: 15051757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.